To view digital features for this article go to Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are successfully used in the treatment of type 2 diabetes mellitus, improving glycaemic control with low risk of hypoglycaemia and inducing weight loss [1, 2]
However, participants who were early responders (having lost 10% starting body weight by week 16) saw an average of up to 22% weight loss
High prevalence of metabolic obesity in India: The ICMR-INDIAB national study (ICMR-INDIAB-23).The Indian journal of medical research,161461-472 2
Patients were randomly assigned in a 2:1 ratio to receive cabozantinib (140 mg per day) or placebo
Importantly, around one-third of participants achieved at least 20% weight loss, demonstrating the potential for clinically meaningful weight reduction in suitable patients
Mild reactions are common, but know when to get help: A small amount of redness, itching, swelling or a bruise can be normal